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tude of the effect of ramipril in women vs. men. 
Conclusions: ACE inhibition with ramipril is highly effective in high-risk women without HF 
and with preserved LVEF. 
Effect of Ramlprll In Women 
Placebo (n=1201) Ramipril (n=1279 RR (95% CI) p 
MI, stroke, CV death 179 (14.9%) 145 (11.3%) 0.76 (0.61-0.94) 0.01 
MI 113 (9.4%) 105 (8.2%) 0.87 (0.67-1.14) 0.3 
Stroke 58 (4.8%) 40 (3.1%) 0.61 (0.43-0.86) 0.004 
CV Death 139 (11.6%) 118 (9.2%) 0.79 (0.62-1.02) 0.06 
Revascularizations 173 (14.4%) 150 (11.7%) 0.81 (0.65-1.00) 0.05 
Heart Failure 136 (11.3%) 117 (9.2%) 0.81 (0.63-1.03) 0.08 
Worsening Angina 312 (26.0%) 275 (21.5%) 0.80 (0.68-0.94) 0.007 
New Diabetes 27 (4.7%) 16 (2.7%) 0.58 (0.31-1.08) 0.08 
1051-29 Effects of Vitamin E on Cardiovascular and 
Microvascular Outcomes in High-Risk Diabetic Patients 
Eva Lonn. Hertzel Gerstein, Janice Pogue, Qilong Yi, Byron J. Hoogwerf, Jacqueline 
Bosch, GUles Dagenais, Salim Yusuf, McMaster Universi~ Hamilton, Ontario, Canada. 
Background: Oxidative stress is an important mechanism of atherogenesis and 
microvascular damage in diabetes. Elevated protein kinase C (PKC) may also increase 
microvascular damage. Vitamin E is an antioxidant and decreases PKC activation. 
Methods: We evaluated natural source Vitamin E (RRR-alpha-tocopheryl acetate) 400 
IU/day vs. placebo in 3,654 high-risk persons with diabetes enrolled in the randomized 
controlled Heart Outcomes Prevention Evaluation (HOPE) trial. Median follow-up was 
4.5 years. Data on major clinical outcomes were collected. Glycated hemoglobin (HbAlc) 
and serum creatinine were measured at baseline and yearly thereafter. Urinary albumin 
excretion was measured at baseline, 1 year and study end. Participants with albumin/ 
creatinine ratio higher than 36 mg/mmol had 24 hour urine collections. Nephropathy was 
defined as 24-hour urinary albumin excretion of 300 mg or more or total protein excretion 
of 500 mg or more. 
Results: Baseline characteristics were well balanced. Patients' mean age was 65 years, 
3,572 had type 2 diabetes, 1,356 were women, 2,189 had known CAD, 244 had prior 
stroke, 678 peripheral arterial disease, 2,031 hypertension, 2,384 hypercholesterolemia. 
Major event rates (in %) were similar in the 2 groups (Table). Serial measurements of 
HbAlc, urinary albumin/creatinine ratio and serum creatinine were also similar in the 2 
groups. 
Conclusions: Vitamin E 400 IU/day has a neutral effect on CV outcomes and microvas- 
cular complications in high-risk diabetics, 
CV and Mlcrovasculsr Event Rates (in %) 
Placebo (n=1816) Vitamin E (n=1838) RR (95% CI) 
MI, Stroke and CV Death 17.2 17.7 1.03 (0.88-1.21) 
MI 11.5 11.5 1.01 (0.83-1.22) 
Stroke 4.6 5.6 1.21 (0.91-1.62) 
CV Death 8.0 7.7 0.97 (0.77-1.23) 
Total mortality 12.8 11.9 0.93 (0.77-1.12) 
Heart failure 4.2 4.6 1.11 (0.81-1.51) 
Revascularizations 15.3 15.2 0.99 (0.82-1.17) 
Overt Nephropathy 7.2 7.9 1.12 (0.88-1.44) 
New Microalbuminuria 37.5 35.3 0.91 (0.79-1.03) 
Retinal Laser Therapy 10.0 9.9 0.99 (0.81-1.22) 
1051-30 Pharmacodynamic Interactions Between Tadalafil and 
Nitrates 
Robert Kloner. Jeff Emmick, Alun Bedding, Dennis Humen, Eli Lilly and Company, Erl 
Wood Manor, United Kingdom. 
Background: Tadalafil is a selective PDE5 inhibitor under regulatory review for the treat- 
ment of erectile dysfunction. Because sildenafil, another PDE5 inhibitor, is contraindi- 
cated in men taking nitrates, studies were undertaken to examine potential interactions 
between tadalafil and nitrates. Methods: Two double-blind, randomized, 3-way cross- 
over studies were conducted in patients with stable angina to determine: 1) Study A - 
response to sublingual nitroglycerin (SL NG) administered 2 hours after tadalafil 5 or 10 
m 9 or placebo (n=51); and 2) Study B - response after tadalafil 5 or 10 mg or placebo 
administered during daily long-acting nitroglycerin (LA NG) therapy (n=45). Reeulls: The 
table shows the results for the primary endpoint, which was mean maximal change in 
standing systolic BP (MMCSBP). 
Comparative Analysis of Standing MMCSBP Between Treatment Groups (mmHg) 
Tadalafil (10 mg)-Placebo Tadalafil (5 mg)-Placebo 
Mean Lower Bound of Mean Lower Bound of 
Difference 95% CI Difference 95% CI 
Study A (SL NG) -3 -6 -8* -12 
Study B (LA NG) -2 -6 0 -4 
*Mean difference statistically significant based on non-inferiority analysis 
Numbers of Patients with Standing SBP <85 mmHg (outliers) 
Placebo Tadalafil 5 mg Tadalafi110 m 9 
Study A (SL NG) 1 13 11 
Study B (LA NG) 0 0 6 
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There were no statistically significant differences in either study between tadalafil 5 or 10 
mg and placebo in the sitting position. Conclusions: Tadalafil had minimal effects, rela- 
tive to placebo, on mean blood pressure changes induced by either SL NG or LANG. 
However, the frequency of outliers was higher in the tadalafil treatment groups, indicating 
that in a subset of patients, tadalafil augments the decrease in BP induced by nitrates. 
These results suggest that, as with sildenafil, tadalafil should not be used in combination 
with nitrates. 
1051-45 Randomized Comparison of Exercise Training Versus 
PTCA/Stent in Stable Coronary Artery Disease: Effects 
on Clinical Status and Maximal Exercise Capacity 
Katrin Conradi, Sven M6bius-Winkler, Claudia Walther, Peter Sick, Jiangtao Yu, Kai 
Kenziorra, Regine Kluge, Rainer Hambrecht, Gerhard Schuler, University of Leipzig, 
Heart-Center, Department of Cardiology, Leipzig, Germany, University of Leipzig, 
Department of Nuclear Medicine, Leipzig, Germany. 
Introduction: In patients (pts) with stable coronary artery disease (CAD) regular exercise 
training has the therapeutic potential to improve physical work capacity (PWC). The aim 
of the present study was to evaluate the effects of exercise training in comparison to an 
interventional approach (PTCA and stent implantation) in pts with symptomatic CAD with 
respect to symptom-free PWC. 
Methods: 100 male pts with stable CAD (amenable for PTCA/stent implantation) were 
prospectively randomized to either a training (T, n=50) or an intervention group (INT, 
n=50). Pts of the training group exercised 20 minutes daily on a bicycle ergometer 
whereas pts in the intervention group received initially a PTCNstent implantation. At the 
beginning and after 6 months patients underwent a maximal symptom limited exercise 
stress test to assess PWC and maximal oxygen uptake (VO2 max). 
Results: After 6 months pts of both groups demonstrated a significant improvement in 
clinical status from 1.33±0.13 to 0.6±0.11 (CCS-class, p<0.01 vs. begin) in T and 
1.65±0.11 to 1.02±0.12 (p<0.01 vs. begin) in INT, respectively. Regular exercise training 
was associated with a significant increase in PWC (132=4.1 to 161±5 Watt; p<0.05 vs, 
INT) and peak oxygen uptake ( 22.2±0.6 to 25.3±0.9 mL./kgxmin, p<0.05 vs. INT) in T, 
whereas INT showed no difference (119=3,4 to 124±4 Watt, n.s.; 20.8±0.6 to 
21.5=0.7mL/kgxmin, n.s.) Twenty-six pts of T and fifteen of INT were completely free of 
clinical symptoms after 6 months 
Conclusions: These data suggest that in a selected daily physical exercise training 
seems to be a feasible alternative to an interventional approach with respect to clinical 
status and functional work capacity. 
1051-46 Assessment of Reperfusion Therapy on Regional and 
Global Left Ventricular Function in Patients With 
Chronic Total Coronary Artery Occlusions 
Cenaiz Ermis. AdU Boz, Venkat Tholakanahalli, Selim Yalcinkaya, Ender Semiz, Oktay 
Sancaktar, Leslie W. Miller, Necmi Deger, David G. Benditt, Cardiovascular Division, 
University of Minnesota, Minneapolis, Minnesota, Cardiovascular Division, University of 
Akdeniz, Antalya, Turkey. 
Background: The regional and global ventricular function benefit achieved by percutane- 
ous coronary intervention (PCI) with repertusion of the artery supplying the infarct area in 
acute myocardial infarction (AMI) is well described. In addition, several trials indicate that 
PCt in AMI, reduces morbidity and mortality. Conversely, although the survival benefit of 
PCI in the setting of chronic total coronary occlusion (CTO) has recently been shown to 
be of little value, little is known of the potential effects on regional and global left ventricu- 
lar function after late recanalization of CTO. This prospective study examined whether 
PCI improves regional and global left ventricular function (LVF) in CTO. 
Methods: Patients (pts) having at least one coronary artery occluded for >6 weeks dura- 
tion, were included in the study. Exercise TI-201 myocardial perfusion scintigraphy 
(TMS), multiple gated acquisition (MUGA) ventriculography, and 2-dimensional echocar- 
diography (Echo) were performed in each pt to assess both regional and global LVF 
before and 6 weeks after PCI. Paired sample t-tests were utilized for statistical analysis. 
Results: Thirty-five pts were enrolled in the study. Fifteen pts were subsequently 
excluded because of inability to open the artery and one because of emergent angio- 
plasty. In the remaining 19 pts (16 male and 3 female, mean age of 58=5 years) ejection 
fraction (EF) pre and post PCI, was 51±7% and 58±6% using Simpson's method 
(p<0.001) by Echo, and it was 45=1% and 53=1% (p<0.01) by MUGA, respectively. 
Echocardiographic wall motion score was 24±9 before and 15±6 (p<0.001) after PCI. 
Exercise perfusion score (21±1 and 14±1 [p=0.01]), rest perfusion score (15±1 and 12±1 
[p=0.02]), and re-injection perfusion score (14=1 and 11=1 [p =0.07]) all also improved. 
Conclusion: Percutaneous coronary reperfusion therapy significantly improved the 
regional and global left ventricular function in patients with chronic total coronary occlu- 
sion. Thus, although PCI may not benefit survival in CTO pts, improvement in ventricular 
function may provide important symptom benefits. 
1051-47 Nitric Oxide Activity in Complex Atheromatous Plaques 
Dimitris Tousoulis. Costas Tentolouris, Tom Crake, Costas Toutouzas, Athansios Trikas, 
Christos Pitsavos, Christodoulos Stetanadis, Graham Davies, Pavlos Toutouzas, 
Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, 
Greece, Cardiology Unit, Hammersmith Hospital, London, United Kingdom. 
Background: Administration of L-arginine (LA) may stimulate the release of nitric oxide 
and improve myocardial ischemia.We sought to examine the effects of LA administration 
on coronary stenosis vasomotion in patients with coronary artery disease (CAD). 
Methods: Intracoronary infusions o1 normal saline, the receptor mediated nitric oxide 
stimulant LA (50 and 150 I~mol/min) and nitroglycerin (GNT) (250 mcg bolus) were 
administered in 15 patients with CAD and stable angina. Coronary stenoses were classi- 
fied as smooth (smooth with regular borders) or complicated (irregular borders). The 
